The transcription factor Zeb2 regulates development of conventional and plasmacytoid DCs by repressing Id2 by Scott, Charlotte et al.
Br ief Definit ive Repor t
The Rockefeller University Press  $30.00
J. Exp. Med. 2016 Vol. 213 No. 6 897–911
www.jem.org/cgi/doi/10.1084/jem.20151715
897
DCs reside in almost all tissues in the body, where they func-
tion as immune sentinels. DCs can be subdivided into two 
main groups: plasmacytoid DCs (pDCs), which are special-
ized in the production of type I interferons to elicit an an-
tiviral immune response (Swiecki and Colonna, 2015), and 
conventional DCs (cDCs), which are professional antigen- 
presenting cells. cDCs form the crucial link between the in-
nate and adaptive arms of the immune system by sampling 
local antigens and subsequently migrating to their draining 
LNs, where they initiate appropriate responses from T cells 
(Merad et al., 2013). cDCs exist in two main subtypes, which 
were recently termed cDC1s and cDC2s (Guilliams et al., 
2014). cDC1s, expressing XCR1 and usually CD103 and/
or CD8α, are functionally specialized in cross-presentation 
of antigens to CD8+ T cells (Hildner et al., 2008; Bachem et 
al., 2010; Haniffa et al., 2012). cDC2s express CD172a (signal 
regulatory protein α [SIRPα]) and usually CD11b or CD4 
and are functionally specialized in the presentation of anti-
gens to CD4+ T cells (Merad et al., 2013).
DCs develop in the BM through a series of differentia-
tion intermediates, each with a further degree of commitment 
to a specific lineage, that see the common myeloid progenitor 
(CMP) become a macrophage–DC progenitor (MDP) and 
then a common DC progenitor (CDP), with the penultimate 
step of differentiation resulting in generation of the pre-pDC 
and pre-cDCs (Naik et al., 2007; Liu et al., 2009; Merad et 
al., 2013; Onai et al., 2013). Furthermore, it has recently been 
shown that pre-cDCs can be further subdivided into pre-
cDC1s and pre-cDC2s, which are committed to the cDC1 
and cDC2 lineages, respectively (Grajales-Reyes et al., 2015; 
Schlitzer et al., 2015). Pre-pDCs develop into pDCs in the 
BM, which then migrate out to the periphery, whereas the 
pre-cDC subsets first migrate to the periphery and then un-
dergo their final differentiation into cDCs (Liu et al., 2009; 
Onai et al., 2013; Schlitzer et al., 2015). The development of 
pDCs, cDC1s, and cDC2s requires the concerted action of 
several lineage-determining transcription factors (TFs). The 
main TF involved in pDC development and maintenance is 
the basic helix–loop–helix E protein E2-2 (Cisse et al., 2008; 
Ghosh et al., 2010), whereas cDC1s require Irf8, Batf3, and 
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Id2 (Hacker et al., 2003; Tamura et al., 2005; Tailor et al., 2008; 
Edelson et al., 2011; Jackson et al., 2011; Grajales-Reyes et al., 
2015). Notch2 (Lewis et al., 2011; Satpathy et al., 2013), Klf4 
(Tussiwand et al., 2015), and more recently Irf4 (Bajaña et al., 
2016) have been shown to be required for terminal differ-
entiation into tissue-specific cDC2 subsets but do not seem 
to be involved in the early commitment toward the cDC2 
lineage in the BM. Additionally, Irf4 has also been implicated 
in the survival of differentiated cDC2s, as well as in their mi-
gration to the LNs (Tamura et al., 2005; Persson et al., 2013b; 
Schlitzer et al., 2013; Williams et al., 2013). However, the TFs 
involved in the initial specification and commitment toward 
the cDC2 lineage have not yet been identified, and much 
remains unknown regarding how the decision to commit to a 
specific DC lineage is made (Murphy, 2013).
Zinc finger E box –binding homeobox 2 (Zeb2) is a TF 
primarily associated with the epithelial–mesenchymal transi-
tion, a process important in embryonic development, wound 
healing, and cancer progression (De Craene and Berx, 2013). 
However, Zeb2 has also been implicated in the development 
of the nervous system and is known to be required for normal 
mouse melanocyte differentiation and embryonic hemato-
poiesis (Goossens et al., 2011; Denecker et al., 2014; Hegarty 
et al., 2015). Although its role in the immune system is largely 
unknown, Zeb2 has recently been shown to be required for 
the maturation of NK cells (van Helden et al., 2015) and 
terminal differentiation of T cells (Dominguez et al., 2015; 
Omilusik et al., 2015). Zeb2 has also been identified in tran-
scriptional analyses as a potential TF involved in DC develop-
ment (Miller et al., 2012; Grajales-Reyes et al., 2015; Schlitzer 
et al., 2015). Here, we use mice either lacking or ectopically 
expressing Zeb2 in CD11c+ cells to examine the effects of 
manipulating Zeb2 expression in DCs. We demonstrate that 
Zeb2 is required for the development of pDCs and cDC2s 
in vivo, with Cd11cCrexZeb2fl/fl cells being more efficient at 
generating cDC1s, which is associated with a rise in the E 
protein inhibitor Id2. Reciprocally increasing the expression 
of Zeb2 resulted in a decrease in the cDC1 population with 
an associated increase in cDC2 development. Thus, Zeb2 is 
a previously uncharacterized key player in the regulation of 
the decision of DC precursors to commit to a specific DC 
lineage by mediating Id2 expression.
RES ULTS AND DIS CUS SION
High expression of Zeb2 beyond the CDP stage and 
in subsets of mature DCs
Zeb2 has recently been identified in several genome-wide 
microarrays and RNA-sequencing transcriptional analyses 
as a TF associated with cDC2 development and found to 
be expressed in pre-cDC2s and cDC2s (Miller et al., 2012; 
Schlitzer et al., 2015) but down-regulated in pre-cDC1s and 
cDC1s (Grajales-Reyes et al., 2015). To validate these results 
and determine at which stages in DC development Zeb2 
could play a role, we FACS purified CMPs, MDPs, CDPs, 
and pre-pDCs from the BM and pDCs, pre-cDC1s, pre-
cDC2s, cDC1s, and cDC2s from the spleen and performed 
RT–quantitative PCR (qPCR) analysis for Zeb2 expression. 
In agreement with published data, we found Zeb2 mRNA 
expression to be increased in pre-cDC2s and decreased in 
pre-cDC1s compared with CDPs (Fig. 1 A; Grajales-Reyes 
et al., 2015; Schlitzer et al., 2015). Strikingly, we also found 
Zeb2 to be up-regulated in pre-pDCs and pDCs, suggesting a 
role for this TF in pDCs (Fig. 1 A). As Zeb2 has recently been 
implicated in NK cell (van Helden et al., 2015) and T cell 
development (Dominguez et al., 2015; Omilusik et al., 2015), 
we also FACS purified NK cells and CD4+ and CD8+ T cells 
as a reference for Zeb2 expression levels. cDC2s and pDCs 
expressed lower levels of Zeb2 than NK cells but higher levels 
of Zeb2 than both T cell subsets (Fig. 1 A).
Splenic pDCs and cDC2s are reduced in  
Cd11cCrexZeb2fl/fl mice, whereas splenic cDC1s  
are reduced in Cd11cCrexR26-Zeb2Tg/Tg mice
To examine whether Zeb2 expression has a functional role in 
cDCs and/or pDCs, we generated mice lacking or ectopically 
expressing either one or both alleles of Zeb2 in CD11c+ cells, 
including pre-cDCs, cDCs, and pDCs, by crossing Cd11cCre 
mice (Caton et al., 2007) with Zeb2fl/fl mice (Higashi et al., 
2002) or with R26-Zeb2Tg/Tg mice (Tatari et al., 2014) to 
drive transgenic Zeb2 expression from the Rosa-26 promoter 
(Fig. 1 B). Analysis of Zeb2 mRNA levels in the splenic pDC 
populations of these mice revealed a slight down-regulation 
of Zeb2 in the Cd11cCrexZeb2fl/fl mice (Zeb2−/− mice) and 
a striking up-regulation of Zeb2 in the Cd11cCrexR26-Zeb2Tg/Tg 
mice (Zeb2Tg/Tg mice; Fig. 1 C and Fig. S1, A and B). De-
spite the only slight down-regulation of Zeb2 observed in the 
remaining pDCs in Zeb2−/− mice, there was a significant re-
duction in the pDC population in Zeb2−/− mice in the spleen 
and the blood (Fig. 1, D and E; and Fig. S1, C–E), suggesting 
Zeb2 expression is indeed down-regulated in pDCs. Inter-
estingly, loss of only one allele of Zeb2 (Zeb2+/−) had only 
minimal effects on the pDC population (Fig. 1, D and E; and 
Fig. S1 D), demonstrating that although Zeb2 is a crucial TF 
for pDC homeostasis, haplo-sufficient expression is able to 
generate a normal pDC population. Increasing expression of 
Zeb2 in pDCs did not result in any significant changes in the 
proportion of pDCs, but we did observe an increase in terms 
of absolute cell numbers (Fig. 1, D and E; and Fig. S1 D). We 
hypothesize that this is because pDCs already express high 
levels of Zeb2 in steady state, and so the moderate increase in 
Zeb2 expression driven by the Rosa-26 promoter does not 
provide significant advantages to the cells.
Analysis of the cDC populations in Zeb2−/− and 
Zeb2Tg/Tg mice revealed a striking down-regulation of Zeb2 
expression among cDC2s in Zeb2−/− mice and a significant 
up-regulation of Zeb2 expression among cDC1s in Zeb2Tg/Tg 
mice (Fig. 1 F and Fig. S2). Ablation of Zeb2 in cDC1s did 
not cause any significant decrease in Zeb2 expression, likely 
because WT cDC1 cells do not express Zeb2. There was also 
no significant increase in Zeb2 levels in cDC2s in Zeb2Tg/Tg 
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Figure 1. Zeb2 expression levels regulate pDCs and cDCs. (A) RT-qPCR for Zeb2 expression in FACS-purified BM-derived CMPs, MDPs, CDPs, and pre-
pDCs and splenic pDCs, pre-cDC1s, pre-cDC2s, cDC1s, cDC2s, CD4+ T cells, CD8+ T cells, and NK cells from WT mice. Results shown are expressed relative to 
GAP DH expression using the 2−ΔΔC(t) method with CMP set to 1. Data are pooled from two to three experiments, with at least n = 4 per cell type. Two-way 
Student’s t test was used between indicated groups. (B) Schematic showing range of Zeb2 levels and abbreviations for the transgenic mice lines used in the 
study. Zeb2+/+ = Zeb2fl/fl, Zeb2fl/+, Zeb2Tg/Tg, or Zeb2+/Tg; Zeb2+/− = Cd11cCrexZeb2fl/+; Zeb2−/− = Cd11cCrexZeb2fl/fl; Zeb2+/Tg = Cd11cCrexZeb2Tg/+; and Zeb2Tg/Tg 
= Cd11cCrexZeb2Tg/Tg. (C) Splenic pDCs were FACS purified from Zeb2−/−, Zeb2+/+, and Zeb2Tg/Tg mice, and Zeb2 levels were assessed by RT-qPCR. The results 
shown are expressed relative to GAP DH expression using the 2−ΔΔC(t) method with Zeb2+/+ pDCs set to 1. Data are pooled from two experiments, with at least 
n = 7 per group. Two-way Student’s t test was used. (D) Proportion of splenic pDCs as a percentage of live lineage−CD11b− cells in Zeb2+/+, Zeb2+/−, Zeb2−/−, 
Zeb2+/Tg, and Zeb2Tg/Tg mice. Data are pooled from two experiments with at least n = 8 per group. One-way ANO VA with Bonferroni posttest was used. 
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mice (Fig. 1 F). Fitting with the high mRNA expression data 
for Zeb2 in cDC2s, we found that in addition to the severe 
reduction in pDCs, ablation of Zeb2 expression in CD11c+ 
cells resulted in a reduction in the proportion and absolute 
number of XCR1−SIRPα+ cDC2s (Fig. 1, G and H; and Fig. 
S3). Somewhat surprisingly, this reduction was coupled with 
an increase in both the proportion and absolute number of 
XCR1+SIRPα− cDC1s (Fig. 1, G and H; and Fig. S3). Simi-
larly to the pDCs, this reduction in cDC2s was only apparent 
when both alleles of Zeb2 were targeted (Fig. 1, G and H; 
and Fig. S3). On the contrary, two alleles of the transgenic 
Zeb2 in CD11c+ cells led to a decrease in the proportion 
and number of splenic cDC1s, whereas the cDC2s were un-
affected. As hypothesized with the pDCs, we believe that this 
is because the Rosa-26 promoter does not significantly in-
crease the level of Zeb2 expression in this subset. Once again, 
we observed that only targeting one allele had limited effects 
on either subset (Fig. 1, G and H; and Fig. S3). Interestingly, 
the increased expression of Zeb2 in CD11c+ cells led to the 
presence of a new XCR1+SIRPα+ population of cDCs in 
the spleen (Fig. 1, G and H; and Fig. S3). To our knowledge, 
the presence of such a population has not previously been 
reported. These XCR1+SIRPα+ (double positive [DP]) cDCs 
also expressed intermediate levels of CD24, a marker typically 
associated with cDC1s (Fig. 1 I), suggesting these cells rep-
resent an intermediate subset between a cDC1 and a cDC2.
Zeb2 expression differentially affects subsets 
of tissue-resident cDC2s
We next extended our analysis to the liver, lung, and small 
intestine (SI) lamina propria (LP) to determine whether Zeb2 
expression regulates cDCs globally or whether its role is re-
stricted to lymphoid tissues. Analysis of cDC1s and cDC2s 
on the basis of XCR1 and SIRPα expression in these tissues 
revealed, similarly to the spleen, an overall increase in cDC1s 
and decrease in cDC2s in Zeb2−/− mice and an overall de-
crease in cDC1s in Zeb2Tg/Tg mice (Fig.  2), demonstrating 
that Zeb2 expression in CD11c+ cells regulates cDC sub-
set development across all these mouse tissues. However, the 
scale of these differences was tissue dependent, suggesting the 
involvement of some local tissue-imprinting factors. For ex-
ample, we did not observe any effect of Zeb2 overexpression 
in the liver (Fig.  2, A and B; and Fig. S4 B), whereas the 
lung cDCs appeared to be extra sensitive to Zeb2 expres-
sion levels with effects of Zeb2 loss and overexpression being 
observed even when only one allele of Zeb2 was targeted 
(Fig. 2, C and D; and Fig. S4 C). Additionally, a population 
of XCR1−SIRPα− cDCs was identified in the lungs of the 
Zeb2−/− and Zeb2+/− mice (Fig. 2 C). In the SI LP, the same 
trends were observed in terms of total cDC1s and cDC2s 
as in the other tissues (Fig. 2, E and F). However, when the 
cDC2s were further subdivided on the basis of CD103 ex-
pression, a marker commonly used to define cDC subsets in 
the gut (Persson et al., 2013a; Scott et al., 2015), we found that 
the two subsets of cDC2s were not equally sensitive to Zeb2 
expression. Intriguingly, we found the CD103− cDC2s to be 
highly susceptible to the loss of Zeb2 expression, whereas 
the CD103+ cDC2s appeared to be unaffected in Zeb2−/− 
mice. No effects were seen in either population in Zeb2Tg/Tg 
mice, with only the cDC1s (CD103+SIRPα−) being affected 
(Fig. 2, G and H; and Fig. S4, A and D). Analysis of the resident 
cDC populations in the mesenteric LN (MLN) found similar 
trends within the cDC1 and cDC2 populations in Zeb2+/+, 
Zeb2−/−, and Zeb2Tg/Tg mice (Fig. 2  I). As observed in the 
spleen, a DP cDC population was present among the resident 
cDCs in the Zeb2Tg/Tg mice (Fig. 2  I). Examination of the 
migratory cDCs in the MLN found similar trends to that ob-
served in the SI LP (Fig. 2 J), confirming that Zeb2 expression 
does not affect mature cDC migration to the draining LNs.
DC-intrinsic effects of Zeb2 expression on cDC commitment 
revealed by competitive BM chimerism
Having shown that Zeb2 expression in CD11c+ cells reg-
ulates both pDCs and cDCs, we next sought to determine 
whether these effects were cell intrinsic or caused by immune 
dysregulation. To this end, we generated competitive BM chi-
meric mice (Fig. 3 A), in which CD45.1/CD45.2 WT mice 
were lethally irradiated and reconstituted with an ∼70:30 
mix (determined by analysis of neutrophils in the spleen; 
Fig. 3 B and Fig. S5 A) of Zeb2fl/fl/Zeb2Tg/Tg (Zeb2+/+), Cd-
11cCrexZeb2fl/fl (Zeb2−/−), or Cd11cCrexZeb2Tg/Tg (Zeb2Tg/Tg) 
CD45.2+ BM and WT CD45.1+ BM. 10–12 wk after recon-
stitution, the proportions of CD45.2+ cells among pDCs in 
the spleen and cDC1s and cDC2s in the spleen, lung, liver, 
and SI LP were analyzed. This analysis revealed that the de-
fect in pDCs in the Zeb2−/− mice was indeed cell intrin-
sic, with the Zeb2−/− CD45.2+ cells dramatically losing the 
competition with the CD45.1+ WT BM to generate pDCs 
(E) Representative FACS plots showing identification of CD317+CD45R+ pDCs in the spleen of Zeb2+/+, Zeb2+/−, Zeb2−/−, Zeb2+/Tg, and Zeb2Tg/Tg mice. Cells 
were pregated as single live lineage−CD11b− and were Ly6C+MHC IIintCD11cint. Numbers represent proportion of pDCs as a percentage of live Lin−CD11b− 
cells. (F) Splenic cDC1s and cDC2s were FACS purified from Zeb2+/+, Zeb2−/−, or Zeb2Tg/Tg mice, and Zeb2 levels were assessed by RT-qPCR. The results shown 
are expressed relative to GAP DH expression using the 2−ΔΔC(t) method with Zeb2+/+ cDC1s set to 1. Data are pooled from two to three experiments, with at 
least n = 7 per group. Two-way Student’s t test was used. (G) Proportion of splenic cDC1s, cDC2s, and DP cDCs as a percentage of total cDCs in Zeb2+/+, 
Zeb2+/−, Zeb2−/−, Zeb2+/Tg, and Zeb2Tg/Tg mice. Data are pooled from two to three experiments, with at least n = 4 per group. One-way ANO VA with Bonfer-
roni posttest was used. (H) Representative FACS plots showing identification of XCR1+SIRPα− cDC1s, XCR1−SIRPα+ cDC2s, and XCR1+SIRPα+ DP cDCs in 
the spleen of Zeb2+/+, Zeb2+/−, Zeb2−/−, Zeb2+/Tg, and Zeb2Tg/Tg mice. Cells were pregated as single live lineage−CD26+CD11c+MHC II+F4/80−CD64−. Numbers 
represent proportion of cDC1s, cDC2s, and DP cDCs as a percentage of total cDCs. (I) Representative histogram showing CD24 expression by splenic cDC1s, 
cDC2s, and DP cDCs in Zeb2Tg/Tg mice. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Error bars represent SEM. AU, arbitrary units.
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when compared with their Zeb2+/+ counterparts (Fig. 3 B 
and Fig. S5 B). Consistent with our earlier findings that in-
creasing Zeb2 expression did not alter the pDC population, 
the WT and Zeb2Tg/Tg BM were equally capable of gener-
ating pDCs (Fig. 3 B and Fig. S5 B). Thus, we can conclude 
that pDCs, in addition to the TF E2-2 (Cisse et al., 2008; 
Ghosh et al., 2010; Murphy, 2013), require Zeb2 expression 
for their homeostasis. Concurrently, we also found the de-
fect in cDC2 generation in the spleen, lung, and liver and 
CD103− cDC2 generation in the SI LP of Zeb2−/− mice to 
be cell intrinsic, demonstrating that Zeb2 expression is also 
required by cDC2s (Fig. 3, B–E; and Fig. S5, C–F). Analysis of 
the cDC1 populations in these tissues also found that the en-
hanced generation of cDC1s in Cd11cCrexZeb2fl/fl mice was 
cell intrinsic, as Zeb2−/− CD45.2+ BM had a competitive ad-
vantage over WT CD45.1+ BM in the generation of cDC1s 
compared with their Zeb2+/+ counterparts (Fig. 3, B–E; and 
Fig. S5, C–F). Similarly, we found that the decrease in spleen, 
lung, and SI LP cDC1s in Cd11cCrexR26-Zeb2Tg/Tg mice was 
cell intrinsic (Fig. 3, B, C, and E; and Fig. S5, C, D, and F), 
as was the generation of DP cDCs, with these being almost 
uniformly derived from Zeb2Tg/Tg BM (Fig. 3 B). However 
Zeb2Tg/Tg BM cells did not show a competitive advantage 
over WT BM in generating cDC2s in the chimeras (Fig. 3, 
B–E; and Fig. S5, C–F). Thus, collectively, we can conclude 
that Zeb2 is necessary for cDC subtype lineage commitment, 
with its absence skewing the cDC population away from the 
cDC2 subtype and its overexpression skewing the cDC pop-
ulation away from the cDC1 population.
Interestingly, analysis of the CD103+ cDC2s in the SI 
LP demonstrated that in addition to having a competitive 
advantage over WT BM to become cDC1s, Zeb2−/− BM 
also outcompeted WT BM to generate CD103+ cDC2s, 
whereas WT BM outcompeted Zeb2Tg/Tg BM to become 
both CD103+ cDC1s and CD103+ cDC2s (Fig. 3 E and Fig. 
S5 F). This finding in combination with the results in Fig. 2 
(E–J) prompted us to examine Zeb2 expression in the three 
SI LP cDC populations. Fitting with our results, we found 
that the CD103+ cDC2s express significantly less Zeb2 than 
their CD103− counterparts, instead expressing similar lev-
els of Zeb2 to the CD103+ cDC1s (Fig. 3 F). Together, this 
demonstrates that Zeb2 is not required for the generation 
of CD103+ cDC2s and that, in terms of Zeb2 dependence, 
these cells are more similar to the CD103+ cDC1s than their 
CD103− cDC2 counterparts. This is not the first example 
where the CD103+ cDC2s behave similarly to their cDC1 
counterparts, as, for example, CSF2R2b−/− mice that have 
reduced cDC1 populations in the periphery also show a re-
duction in CD103+ cDC2s in the SI (Greter et al., 2012; Li 
et al., 2012; unpublished data). However, there is also ample 
evidence that the CD103+ cDC2s represent a unique cDC 
subset in the gut. For example, the CD103+ cDC2s are the 
only intestinal cDCs that have been reported to be Notch2 
dependent (Lewis et al., 2011), targeted in hu-Langerin dip-
theria toxin A mice (Welty et al., 2013), and affected in mice 
that express a truncated form of SIRPα (Scott et al., 2014). 
Thus, it is clear that further research is required to fully un-
derstand the regulation of this cDC2 subset.
Zeb2 expression regulates cDC development
Having shown that Zeb2 expression levels skew the preva-
lence of the cDC subtypes present in multiple tissues, we next 
sought to determine whether Zeb2 functions during cDC2 
development or whether, similar to the previously described 
cDC2 TFs, it functions in terminally differentiated cDC2s. It 
has recently been proposed that commitment to the cDC1 
and cDC2 lineage is already apparent at the pre-cDC level 
such that pre-cDCs can be further subdivided into cDC1- 
and cDC2-committed pre-cDCs on the basis of Ly6C, 
SiglecH, and CD24 expression (Grajales-Reyes et al., 2015; 
Schlitzer et al., 2015). Thus, we first examined the propor-
tions of these pre-cDCs in the BM of Zeb2−/−, Zeb2+/+, and 
Zeb2Tg/Tg mice (Fig. 4 A and Fig. S6). Although no significant 
differences were observed in any of the populations across 
the three genotypes, we did notice a trend toward less pre-
cDC1s with increasing levels of Zeb2 expression (Fig. 4 A), 
consistent with Zeb2 functioning during cDC development. 
Examination of the pre-cDC subsets in the spleen revealed a 
similar trend in pre-cDC1s as observed in the BM, in addition 
to a significant increase in pre-cDC2s with increasing levels 
of Zeb2 expression (Fig. 4 B), further pointing toward a role 
for Zeb2 in controlling cDC2 development. To definitively 
Figure 2. Zeb2 expression differentially affects subsets of tissue-resident cDC2s. (A, C, and E) Representative FACS plots showing identification 
of XCR1+SIRPα− cDC1s and XCR1−SIRPα+ cDC2s in the liver (A), lung (C), and SI LP (E) of Zeb2+/+, Zeb2+/−, Zeb2−/−, Zeb2+/Tg, and Zeb2Tg/Tg mice. Cells were 
pregated as single live CD45+ lineage−CD64−F4/80−MHC II+CD11c+CD26+. The numbers represent the proportion of cDC1s and cDC2s as a percentage of total 
cDCs. (B, D, and F) Proportion of liver (B), lung (D), and SI LP (F) cDC1s and cDC2s as a percentage of total cDCs in Zeb2+/+, Zeb2+/−, Zeb2−/−, Zeb2+/Tg, and 
Zeb2Tg/Tg mice. Data are pooled from two to three experiments, with at least n = 7 per group. (G) Representative FACS plots showing identification of CD103+-
SIRPα− cDC1s, CD103+SIRPα+ cDC2s, and CD103−SIRPα+ cDC2s in the SI LP of Zeb2+/+, Zeb2+/−, Zeb2−/−, Zeb2+/Tg, and Zeb2Tg/Tg mice. Cells were pregated 
as single live CD45+ lineage−CD64−F4/80−MHC II+CD11c+CD26+. The numbers represent the proportion of each cDC subset as a percentage of total cDCs. 
(H) Proportion of SI LP CD103+ cDC1s, CD103+ cDC2s, and CD103− cDC2s as a percentage of total cDCs in Zeb2+/+, Zeb2+/−, Zeb2−/−, Zeb2+/Tg, and Zeb2Tg/Tg mice. 
Data are pooled from two to three experiments, with at least n = 7 per group. (I) Proportion of MLN-resident XCR1+SIRPα− cDC1s, XCR1−SIRPα+ cDC2s, 
and XCR1+SIRPα+ DP cDCs as a percentage of total resident cDCs in Zeb2+/+, Zeb2−/−, and Zeb2Tg/Tg mice. Data are representative of two experiments, with 
n = 5 per group. (J) Proportion of MLN migratory CD103+ cDC1s, CD103+ cDC2s, and CD103− cDC2s as a percentage of total migratory cDCs in Zeb2+/+, 
Zeb2−/−, and Zeb2Tg/Tg mice. Data are representative of two experiments, with n = 5 per group. *, P < 0.05; **, P < 0.01; ***, P < 0.001. One-way ANO VA with 
Bonferroni posttest was used.
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demonstrate that Zeb2 functions during cDC2 development, 
we next crossed the recently described late-Cd11cCre mouse 
(Williams et al., 2013), in which the CRE is not active during 
pre-cDC development but only once the pre-cDCs mature 
into cDCs (Williams et al., 2013), with Zeb2fl/fl and Zeb2-
R26Tg/Tg mice. Analysis of these mice revealed that the loss of 
Zeb2 late in cDC development does not affect the prevalence 
of the cDC subsets (Fig. 4 C). Additionally, the effects of over-
expressing Zeb2 were minimized in these mice (Fig. 4 C). 
Thus, we can conclude that Zeb2 functions to maintain the 
balance between cDC1s and cDC2s during development.
Minimal changes in transcriptomes of mature cDC subsets
Having identified Zeb2 as a regulator of cDC development, 
we next sought to examine the consequences of differential 
Zeb2 expression levels in the mature cDCs. To this end, we 
FACS purified cDC1s and cDC2s from Zeb2−/−, Zeb2+/+, 
and Zeb2Tg/Tg mice and performed RNA-sequencing anal-
ysis (Fig. S2, gating strategies). Cluster analysis of this data 
demonstrated that, fitting with our earlier analysis, the ab-
lation of Zeb2 expression in cDC1s and overexpression of 
Zeb2 in cDC2s did not have significant effects on the tran-
scriptomes (Fig. 5 A). To confirm this, we used a visualization 
method in which each gene is plotted in a graph containing 
three axes (one axis per genotype) that are placed at a 120° 
angle, creating a hexagonal triwise plot (Fig. 5 B). In these 
hexagons, the direction of a point represents an up-regula-
tion in one or two populations, whereas the distance from 
the origin represents the magnitude of the up-regulation. 
Each grid line represents a log2 fold change (FC). Plotting 
all uniquely annotated genes for cDC1s and cDC2s yielded 
a horizontal profile with most differentially expressed genes 
in cDC1s either being up-regulated specifically in Zeb2Tg/
Tg mice or in both Zeb2−/− and Zeb2+/+ mice (Fig. 5 B). 
Conversely, in the cDC2s, differentially expressed genes 
were either up-regulated solely in Zeb2−/− mice or in both 
Zeb2+/+ and Zeb2Tg/Tg mice (Fig. 5 B), confirming the clus-
ter analysis. Thus, we subsequently focused our analysis on 
cDC2s from the Zeb2−/− mice and the cDC1s from the 
Zeb2Tg/Tg mice compared with their Zeb2+/+ counterparts. 
Applying a stringency level where the adjusted p-value was 
equal to 0.01 and the log2 FC was less than −1 or greater 
than 1, we found that 263 genes were differentially expressed 
in Zeb2Tg/Tg cDC1s (Table S1), whereas 118 genes were 
Figure 3. Zeb2 regulation of cDC subsets is cell intrinsic. (A) Com-
petitive BM chimeric mice were generated by lethally irradiating CD45.1/
CD45.2 WT mice and reconstituting with an ∼70:30 mix of Zeb2+/+, Zeb2−/−, 
or Zeb2Tg/Tg CD45.2 BM and WT CD45.1 BM. (B) Proportions of splenic neu-
trophils, pDCs, cDC1s, cDC2s, and DP cDCs deriving from CD45.2 donor BM. 
(C) Proportions of lung cDC1s and cDC2s deriving from CD45.2 donor BM. 
(D) Proportions of liver cDC1s and cDC2s deriving from CD45.2 donor BM. 
(E) Proportions of SI LP CD103+ cDC1s, CD103+ cDC2s, and CD103− cDC2s 
deriving from CD45.2 donor BM. Two-way Student’s t test was used. (F) 
SI LP cDCs were FACS purified from WT mice, and Zeb2 expression was as-
sessed by RT-qPCR. Results shown are expressed relative to GAP DH expres-
sion using the 2−ΔΔC(t) method with CD103+ cDC1s set to 1 . AU, arbitrary 
units. One-way ANO VA with Bonferroni posttest was used. Data are pooled 
from two experiments, with at least n = 6 per group. Error bars represent 
SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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differentially expressed in Zeb2−/− cDC2s (Table S2). To 
our surprise, however, most genes were only just over the 
thresholds, with only a few genes having a log2 FC less than 
−2 or greater than 2. This suggests that once these cDCs 
develop, they behave normally. Fitting with this, we did not 
observe any differences in the ability of these cells to in-
duce naive CD4+ or CD8+ T cell proliferation in the steady 
state (unpublished data); however, further examination of the 
functional consequences of altering Zeb2 expression levels 
during infection and inflammation settings are still required. 
Examining the list of differentially expressed genes for sur-
face receptors enabled us to validate some of the changes 
at the protein level by flow cytometry. In Zeb2−/− cDC2s, 
we were able to confirm changes in CD101, CX3CR1, Si-
glecF, and epithelial cell adhesion molecule protein (EpCam) 
expression (Fig. 5 C). However, some of the differentially 
expressed genes did not translate into altered protein ex-
pression, including CD69 and CCR2 (unpublished data). 
Protein analysis in cDC1s from Zeb2Tg/Tg mice validated 
changes in CD4, CD8α, CD11b, CD38 (Fig.  5  D), and 
CD115 (unpublished data), whereas the slight up-regulation 
of CD101 observed at the mRNA level did not result in 
increased protein expression (unpublished data).
Zeb2 acts as a cDC subset fate switch by 
regulating Id2 expression
Given our findings that Zeb2 functions during development 
to determine the ratio between the two cDC subsets across a 
range of mouse tissues, we next sought to investigate whether 
this is caused by Zeb2 acting as a subset fate switch. To this end, 
we generated a list of cDC1- and cDC2-associated genes across 
a range of tissues by examining the transcriptomes of distinct 
cDC1 and cDC2 subsets available on the Immunological Ge-
nome Project consortium (DC.8+.Sp, DC.8+.MLN, DC.8+.
SLN, DC.103+11b-.Lu, and DC.103+11b-.SI for cDC1s; 
and DC.4+.Sp, DC.4+.MLN, DC.4+.SLN, and DC.103-
11b+24+.Lu for cDC2s). The expression of these genes in 
cDC1s and cDC2s across the range of Zeb2 expression levels 
was then examined. This analysis revealed that the Zeb2Tg/Tg 
cDC1s reduce their expression of some of the cDC1-associ-
ated genes including Alms1, Btla, Cxcr3, Gcsam, Gpr33, Lrrc1, 
Ly75, Met, Pbx1, and Tct39a while increasing their expres-
sion of some of the cDC2-associated genes including Apobec1, 
Clec4a1, Ddx58, Ehf, Itgam, Rtp4, and Sirpa (Fig. 6, A and B). 
Conversely, Zeb2−/− cDC2s increased their expression of some 
of the cDC1-associated genes including Cxcr3, Map4k5, Pbx1, 
Rnf144b, Snx22, Tmeff1, and Tct39a, whereas their expression 
Figure 4. Zeb2 regulates cDC subset development. (A and B) Representative FACS plots showing identification of pre-cDC subsets and proportions of 
pre-cDC subsets in the BM (A) and spleen (B) of Zeb2+/+, Zeb2−/−, and Zeb2Tg/Tg mice. Cells were pregated as single live lineage−CD11c+CD45R−MHC II−/intCD135+-
SIRPαint. The numbers represent the proportion of each pre-cDC subset as a percentage of total pre-cDCs. (C) Proportions of cDC subsets as a percentage of 
total cDCs in the spleen of late-Cd11cCrexZeb2fl/fl (Zeb2−/−) and late-Cd11cCrexZeb2Tg/Tg (Zeb2Tg/Tg) compared with Cre− littermate controls (Zeb2+/+). Data are 
pooled from two experiments, with at least n = 7 per group. *, P < 0.05; ***, P < 0.005. One-way ANO VA with Bonferroni posttest was used.
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of the cDC2-associated genes, with the exception of Zeb2 it-
self, was largely unaffected (Fig. 6, A and B). Together with our 
earlier findings that Zeb2 functions during development, this 
suggests that the absence or overexpression of Zeb2 switches 
the fate of the majority of pre-cDCs, resulting in the devel-
opment of cDC1s or cDC2s, respectively. However, this is not 
100% efficient, as some pre-cDCs do become either cDC2s or 
cDC1s in Zeb2−/− and Zeb2Tg/Tg mice, respectively, and conse-
quently, these express some genes typically associated with the 
alternate subset, but these differences are not sufficient to confer 
functional differences to the subsets, at least in the steady state.
With this finding in mind, we sought to focus further 
on the role of Zeb2 in cDC development. First, we exam-
ined how Zeb2 was induced during cDC development by 
analyzing Zeb2 expression levels in WT BM-derived cDC 
subsets after culture of total BM with the canonical cDC 
growth factors Flt3L or GM-CSF (CSF-2). As it has recently 
been shown that GM-CSF BM cultures consist of both 
monocyte-derived DCs and cDCs (Helft et al., 2015), we 
used MHC II, CD115 (CSF-1R), and CD26 expression to 
delineate cDCs and monocyte-derived DCs in these cul-
ture systems, concentrating our analysis on the CD115− 
CD11c+MHC IIhi cDCs (Fig. S7). Intriguingly, Zeb2 ex-
pression was only induced in cDC2s from the Flt3L cultures 
(Fig. 6 C), demonstrating that Zeb2 expression is induced by 
Flt3L but not by GM-CSF signaling. This is consistent with 
recent findings that cDC2s develop normally in mice lacking 
GM-CSF signaling (Greter et al., 2012).
Having shown that Zeb2 is induced during cDC de-
velopment, we next investigated the effects of manipulat-
ing Zeb2 expression on the other TFs known to function 
in cDC development and terminal differentiation. Analysis 
of Irf8 and Irf4 protein expression in the cDCs of Zeb2−/−, 
Zeb2+/+, and Zeb2Tg/Tg mice revealed a striking decrease in 
Irf8 expression in Zeb2Tg/Tg cDC1s that was coupled with 
a significant increase in Irf4. We also observed a significant 
Figure 5. Altering Zeb2 expression levels affects cDC1 and cDC2 
transcriptomes. (A) Cluster analysis of RNA-sequencing data from splenic 
cDC1s and cDC2s from Zeb2+/+, Zeb2−/−, and Zeb2Tg/Tg mice. (B) To visualize 
differential gene expression between Zeb2+/+, Zeb2−/−, and Zeb2Tg/Tg cDC1s 
or cDC2s, each gene was plotted in a hexagonal triwise diagram in which 
the direction of a point represents an up-regulation in one or two popu-
lations, whereas the distance from the origin represents the magnitude of 
this up-regulation. Genes that are ≥32-fold differentially expressed are 
plotted on the outer grid line. Rose diagrams (top right corner of each 
triwise plot) show the percentages of genes in each orientation. Gray dots 
represent genes that are not differentially expressed. Black dots represent 
statistically significant differentially expressed genes. (C) Representative 
FACS plots showing expression of CD101, SiglecF, epithelial cell adhesion 
molecule (EpCam), and CX3CR1 in Zeb2−/− cDC2s compared with Zeb2+/+ 
cDC2s. Numbers represent the percentage of cDC2s expressing each 
marker. (D) Representative FACS plots showing expression of CD4, CD8α, 
CD11b, and CD38 in Zeb2Tg/Tg cDC1s compared with Zeb2+/+ cDC1s. Num-
bers represent the percentage of cDC1s expressing each marker.
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decrease in Irf4 expression in Zeb2−/− cDC2s, but this was 
not correlated with an increase in Irf8 expression (Fig. 6, D 
and E). Consistent with our early findings of an intermediate 
cDC1/cDC2 phenotype, the DP cDCs in the Zeb2Tg/Tg mice 
expressed intermediate levels of Irf8 and Irf4 (unpublished 
data). In addition to Irf8 and Irf4, the TFs Id2, Batf3, Nfil3, 
RelB, Klf4, and Notch2 have all been implicated in cDC de-
velopment and/or terminal differentiation (Wu et al., 1998; 
Tamura et al., 2005; Caton et al., 2007; Tailor et al., 2008; 
Edelson et al., 2011; Jackson et al., 2011; Kashiwada et al., 
2011; Lewis et al., 2011; Persson et al., 2013b; Schlitzer et al., 
2013; Grajales-Reyes et al., 2015; Tussiwand et al., 2015). As 
the expression levels of these TFs cannot be analyzed with 
flow cytometry, we instead examined their mRNA expres-
sion by RT-qPCR in Zeb2−/− cDC1s and cDC2s compared 
with their Zeb2-sufficient counterparts. Strikingly, we found 
a significant up-regulation of the cDC1-associated TF Id2 
among the Zeb2−/− cDC2 population (Fig. 6 F). Consistent 
with this, we found Id2 to be differentially expressed in the 
RNA-sequencing data from Zeb2Tg/Tg cDC1s and Zeb2−/− 
cDC2s with a log2 FC of −0.6 or 0.6, respectively. We did not 
detect any other significant changes in the other TFs exam-
ined, although there was a trend toward less Nfil3 expression 
in Zeb2−/− cDC2s (Fig. 6 F). To determine whether Id2 ex-
pression was also affected by the loss of Zeb2 early in cDC 
development, we next examined Id2 mRNA levels in the 
cDC1- and cDC2-committed splenic pre-cDC populations. 
Similar to the results seen in the mature cDC populations, 
we found an increase in Id2 expression among the Zeb2−/− 
pre-cDC2s (Fig.  6  G), suggesting that Zeb2 may function 
in cDC2s during development to repress Id2 expression. As 
Id2 is known to suppress pDC development by antagonizing 
the E protein TF E2-2 (Spits et al., 2000; Hacker et al., 2003; 
Cisse et al., 2008; Ghosh et al., 2010), we also checked Id2 
expression in the remaining pDCs in the Zeb2−/− mice. As 
observed for the cDC2s, we found a significant increase in 
Id2 expression among the Zeb2−/− pDCs (Fig. 6 H). Thus, 
mechanistically, Zeb2 appears to function during DC devel-
opment by repressing Id2 expression, facilitating both pDC 
and cDC2 development. As Zeb2 is itself a TF, we next exam-
ined whether this effect was through direct binding of Zeb2 
to the Id2 promoter region or through an indirect mecha-
nism. In silico analysis using PhysBinder (Broos et al., 2013) 
or ConTra (Broos et al., 2011) identified several conserved 
Zeb binding sites (Remacle et al., 1999) in Id2 and the sur-
rounding regions in mice and humans (Fig. S8). Thus, we 
next designed two sets of primers to amplify two overlap-
ping regions (A and B) in the Id2 promoter containing the 
predicted binding site (Fig.  6  I). qPCR was performed on 
chromatin extracted from splenic pDCs and cDC2s of 
Zeb2Tg/Tg mice after chromatin immunoprecipitation (ChIP) 
with an antibody recognizing the FLAG tag present on Zeb2 
in these mice. For both pDCs and cDC2s, we observed a clear 
enrichment for region A, with ∼40% for pDCs and 6% for 
cDC2s, whereas region B was amplified with a percentage of 
enrichment of ∼7% and 5% in pDCs and cDC2s, respectively 
(Fig. 6  J). Thus, Zeb2 binds the E boxes present in the Id2 
promoter, repressing its expression.
Collectively, these results highlight a previously unchar-
acterized role for the TF Zeb2 in regulating DC development 
through modulating Id2 expression (Fig. 6 K). In pDCs, Zeb2 
expression represses Id2, allowing the pDC TF E2-2 to bind 
DNA and induce pDC development, whereas in cDC devel-
opment, Zeb2 functions to regulate commitment toward the 
cDC2 lineage by repressing Id2. As such, Zeb2 represents the 
first TF to be described that is involved in the early lineage 
commitment of pre-cDCs toward the cDC2 lineage.
MAT ERI ALS AND MET HODS
Mice. The generation of Zeb2fl/fl and R26-Zeb2Tg/Tg mice 
was described previously (Higashi et al., 2002; Tatari et al., 
2014). Mice were backcrossed to a C57BL/6 background for 
at least seven generations before crossing with the Cd11cCre 
mice (Caton et al., 2007) or late-Cd11cCre mice (Williams et 
Figure 6. cDC subset fate is dictated by Zeb2 expression levels. (A and B) Heat maps showing relative expression of cDC1 (A)- and cDC2 (B)-asso-
ciated genes normalized per mean expression of each gene in cDC1s and cDC2s from Zeb2+/+, Zeb2−/−, and Zeb2Tg/Tg mice. (C) cDC1s from Flt3L WT BMDC 
cultures and cDC2s from WT Flt3L and WT GM-CSF BMDC cultures were FACS purified, and Zeb2 expression was assessed by RT-qPCR. The results shown 
are expressed relative to GAP DH expression using the 2−ΔΔC(t) method with cDC1s set to 1. Data are pooled from two experiments, with n = 6 per group. (D) 
Representative FACS plots showing Irf8 and Irf4 expression by splenic cDC subsets in Zeb2−/−, Zeb2+/+, and Zeb2Tg/Tg mice. (E) Geometric mean (mean fluo-
rescence intensity [MFI]) of Irf8 and Irf4 expression by splenic Zeb2−/−, Zeb2+/+, and Zeb2Tg/Tg cDCs. Data are pooled from two experiments, with at least n = 6 
per group. (C and E) One way ANO VA with Bonferroni posttest was used. (F) Splenic cDC1s and cDC2s were FACS purified from Zeb2+/+ or Zeb2−/− mice, and 
the indicated TF expression was assessed by RT-qPCR. The results shown are expressed relative to GAP DH expression using the 2−ΔΔC(t) method with Zeb2+/+ 
cDC1s set to 1. Data are pooled from three experiments, with at least n = 3 per group. Two-way Student’s t test was used. (G) Splenic pre-cDC1s and pre-
cDC2s were FACS purified from Zeb2+/+ or Zeb2−/− mice, and Id2 expression was assessed by RT-qPCR. The results shown are expressed relative to GAP DH 
expression using the 2−ΔΔC(t) method with Zeb2+/+ pre-cDC1s set to 1. Data are pooled from two experiments, with at least n = 2 per group. (H) Splenic pDCs 
were FACS purified from Zeb2+/+ or Zeb2−/− mice, and Id2 expression was assessed by RT-qPCR. The results shown are expressed relative to GAP DH expres-
sion using the 2−ΔΔC(t) method with Zeb2+/+ pDCs set to 1. Data are pooled from two experiments, with at least n = 7 per group. (F–H) Two-way Student’s t 
test was used. (I) Schematic representation of the Id2 promoter with predicted E boxes. a and b represent regions amplified by qPCR with primer pair A and 
primer pair B, respectively. TSS, transcription start site. (J) qPCR analysis of ChIP performed against the FLAG tag present on recombinant Zeb2 in splenic 
pDCs and cDC2s of Zeb2Tg/Tg mice. Data are expressed as the percentage of input. Data are pooled from two independent experiments, with n = 2 per group. 
(K) Proposed model for the action of Zeb2 in cDC and pDC development. Error bars represent SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. AU, arbitrary units.
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al., 2013). All mice were bred and maintained at the Vlaams 
Instituut voor Biotechnologie (Ghent University) under spe-
cific pathogen-free conditions and were used between 6 and 
12 wk of age. All experiments were performed in accordance 
with the ethical committee of the Faculty of Science of the 
Vlaams Instituut voor Biotechnologie.
Isolation of tissue leukocytes. For the isolation of liver leuko-
cytes, livers were isolated from PBS-perfused mice, chopped 
finely, and incubated for 15–20 min with 1 mg/ml collagenase 
A (Sigma-Aldrich) and 10 U/ml DNase (Roche) in a shaking 
water bath at 37°C. For the isolation of lung and spleen leu-
kocytes, lungs and spleens were isolated from PBS-perfused 
mice, chopped finely, and incubated for 30 min with 0.2 mg/
ml Liberase TM (Roche) and 10 U/ml DNase (Roche) in a 
shaking water bath at 37°C. SI LP leukocytes were isolated as 
described previously (Cerovic et al., 2013). Pre-cDCs were 
isolated from spleens by gently pressing the spleens through 
a 70-µm filter (no enzymes) to allow for the detection of Si-
glecH. BM cells were obtained by flushing femurs and tibias 
with RPMI. In all instances, except for the SI, red blood cells 
were lysed before staining for flow cytometric analysis.
Flow cytometry and FACS. For flow cytometry, 3–4 × 106 
cells were stained at 4°C in the dark with antibodies (Table 
S3). Intracellular staining of Irf4 and Irf8 was performed after 
fixing and permeabilizing of the cells with a Foxp3 TF-stain-
ing buffer set (eBioscience). Data were acquired on a cell an-
alyzer (LSRFortessa; BD) and analyzed using FlowJo software 
(Tree Star). Cells were FACS purified using a flow cytometer 
(FAC SAria II or FAC SAria III; BD). After sorting, a purity 
check was performed for all samples.
RNA sequencing. 25,000 cDC1s or cDC2s from Zeb2−/−, 
Zeb2+/+, and Zeb2Tg/Tg mice were FACS purified into 500 µl 
of buffer (RLT Plus; QIA GEN) and β-mercaptoethanol. 
RNA was isolated using a micro-RNA isolation kit (QIA 
GEN) and sent to the Vlaams Instituut voor Biotechnol-
ogie Nucleomics facility, where the RNA sequencing was 
performed using a NextSeq sequencer (Illumina). The pre-
processing of the RNA sequencing data was done by Trim-
momatic. The adapters were cut off, and reads were trimmed 
when the quality dropped below 20. Reads with a length <35 
were discarded. All samples passed quality control based on 
the results of FastQC. Reads were mapped to the mouse ref-
erence genome via Tophat2 and counted via HTSeqCount. 
Samples were subsequently analyzed using R/Bioconductor, 
and the DESeq2 procedure was used to normalize the data.
Gene expression analysis by real-time RT-PCR. RNA was pu-
rified from sorted cells using an RNeasy Plus micro kit (QIA 
GEN). RNA was reverse transcribed to cDNA with an 
iScript Advanced cDNA Synthesis kit (Bio-Rad Laborato-
ries). Gene expression was assayed by real-time RT-PCR 
using a SensiFast SYBR No-Rox kit (GC Biotech) on a 
PCR amplification and detection instrument (LightCycler 
480; Roche) with the primers listed in Table S4. Gene ex-
pression was normalized to GAP DH, and the mean relative 
gene expression was calculated using the 2−ΔΔC(t) method.
BMDC cultures. Total BM was harvested from WT mice, and 
2 × 106 cells were cultured in RPMI supplemented with 
Glutamax and Gentamicin in a 6-well plate for 7 d with ei-
ther 250 ng/ml Flt3L and 10% FCS for Flt3L cultures or 20 
ng/ml CSF-2 and 5% FCS for CSF-2 cultures. CSF-2 
BMDCs were further supplemented with additional media, 
FCS, and CSF-2 at day 3 of culture.
Zeb2-FLAG ChIP and Id2 qPCR. FACS-purified pDC and 
cDC2 cells from Zeb2Tg/Tg mice were cross-linked with 1% 
paraformaldehyde in fixation buffer (Active Motive). After 
nuclei isolation, DNA was fragmented with 25 U micrococcal 
nuclease for 20 min at 37°C in micrococcal nuclease–digest-
ing buffer (50 mM Tris-HCl, pH 7.6, 1 mM CaCl2, and 0.2% 
Triton X-100). DNA fragment size (150–500 bp) was con-
firmed after chromatin preparation in a 1.2% agarose gel. The 
fragmented chromatin was incubated with 10 µg FLAG-M2 
(F3165; Sigma-Aldrich) antibody overnight followed by a 
pull-down assay using A/G-conjugated agarose beads (EMD 
Millipore). DNA was purified with an iPure kit (Diagenode), 
and the quality was measured using a 2100 Bioanalyzer sys-
tem with a DNA kit (High Sensitivity; Agilent Technologies). 
Real-time qPCR was performed on a Zeb-predicted binding 
site identified in the Id2 promoter with the following prim-
ers: 5′-TAC CTG ACA AAG AGC TTC CC-3′ and 5′-TTA 
CAT ACA CTG CCC TTG GT-3′ (primer pair A) and 5′-ATG 
TGG CTG CAT CTA GGAA-3′ and 5′-GGG AAG CTC TTT 
GTC AGG TA-3′ (primer pair B). Primers in the coding se-
quence of the GAP DH gene were used as a control of un-
specific binding with the following primers: 5′-TTG AGC 
TAG GAC TGG ATA AGC AGG-3′ and 5′-AGT CCG TAT 
TTA TAG GAA CCC GG-3′. The percentage of enrichment 
to the input was calculated and shown in a bar graph.
Statistical analysis. Groups were compared with a two-way 
Student’s t test, and multiple-group comparisons were per-
formed using one-way ANO VA followed by a Bonferroni 
posttest with Prism Software (GraphPad Software). Samples 
were assumed to be normally distributed with similar vari-
ance between groups. No randomization was used to deter-
mine experimental groups, and no blinding of the investigator 
was performed. Group sizes were determined on the basis 
of previous experience.
Accession numbers. All RNA-sequencing data have been de-
posited in the Gene Expression Omnibus public database 
under accession no. GSE79903.
Online supplemental material. Fig. S1 shows splenic pDCs. 
Fig. S2 shows the splenic cDC sorting strategy and purities. 
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Fig. S3 shows splenic cDC gating strategy and absolute 
numbers. Fig. S4 shows cDCs in other tissues. Fig. S5 shows 
BM chimeras. Fig. S6 shows the pre-cDC gating strategy. Fig. 
S7 shows BMDC gating strategies and sorting purities. Fig. S8 
shows the predicted Zeb binding sites in the Id2 locus. Table 
S1 shows differentially expressed genes of Zeb2+/+ versus 
Zeb2Tg/Tg cDC1s. Table S2 shows differentially expressed genes 
of Zeb2+/+ versus Zeb2−/− cDC2s. Table S3 shows antibodies 
used for flow cytometry. Table S4 shows primers used for RT-
qPCR. Online supplemental material is available at http ://
www .jem .org /cgi /content /full /jem .20151715 /DC1.
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